Inactive Instrument

Highlights LogicBio Therapeutics, Inc.

Equities

LOGC

US54142F1021

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

CANbridge Pharmaceuticals Inc. Announces Update on Collaborations with the Umass Chan Medical School and with Logicbio Therapeutics	23-01-03	CI
AstraZeneca Unit Completes Acquisition of LogicBio Therapeutics	22-11-16	MT
Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.	22-11-14	CI
LogicBio Therapeutics : Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet - Definitive merger agreement with Alexion, AstraZeneca Rare Disease, to acquire LogicBio with transaction - Form 8-K	22-11-14	PU
LogicBio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Revenue $2.7M	22-11-14	MT
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Loss $-0.18	22-11-14	MT
LogicBio Therapeutics, Inc. and CANbridge Care Pharma Hong Kong Limited Enter into the Amended and Restated Exclusive Research Collaboration, License and Option Agreement	22-10-07	CI
AstraZeneca Unit To Buy US Biotech LogicBio Therapeutics	22-10-03	MT
AstraZeneca Unit to Acquire LogicBio Therapeutics; LogicBio Shares Soar	22-10-03	MT
LogicBio Therapeutics Shares Soar on Takeover by AstraZeneca	22-10-03	DJ
Top Premarket Gainers	22-10-03	MT
AstraZeneca to Buy LogicBio Therapeutics for $68 Million	22-10-03	DJ
AstraZeneca Unit to Acquire LogicBio Therapeutics; LogicBio Shares Soar	22-10-03	MT
Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. from a group of shareholders for $68.2 million.	22-10-02	CI
LogicBio Therapeutics, Inc Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE	22-09-21	CI
LogicBio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Reports Q2 Revenue $3.2M	22-08-15	MT
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Reports Q2 Loss $-0.15	22-08-15	MT
Exothera Announces Industrial Scale AAV Manufacturing Collaboration with LogicBio Therapeutics and Polyplus	22-06-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights LogicBio Therapeutics, Inc.

Equities

LOGC

US54142F1021

Highlights

Filters